Royalty Pharma plc Debt Securities, Available-for-sale, Realized Gain
Royalty Pharma plc (RPRX) reported Debt Securities, Available-for-sale, Realized Gain of $0 for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-24.
Discontinued › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleRealizedGain · last filed 2021-02-24
- Royalty Pharma plc debt securities, available-for-sale, realized gain for fiscal 2020 was $0.00.
- Royalty Pharma plc debt securities, available-for-sale, realized gain for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
- Royalty Pharma plc debt securities, available-for-sale, realized gain for fiscal 2018 was $419.48M.
| Period end | Debt Securities, Available-for-sale, Realized Gain 12 month |
|---|---|
| 2020-12-31 | $0.00 10-K · filed 2021-02-24 |
| 2019-12-31 | $0.00 10-K · filed 2021-02-24 |
| 2018-12-31 | $419.48M 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |